New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases

Annals of the New York Academy of Sciences

Volumn 1275, Issue 1, 2012, Pages 85-91

  Tarr, Tyler B ^a   Valdomir, Guillermo ^b   Liang, Mary ^b   Wipf, Peter ^b   Meriney, Stephen D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Calcium channel; Lambert Eaton myasthenic syndrome; Roscovitine; Transmitter release

Indexed keywords

CALCIUM; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; GV 58; ROSCOVITINE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CURRENT; CALCIUM TRANSPORT; CHEMICAL MODIFICATION; DRUG SYNTHESIS; EATON LAMBERT SYNDROME; HUMAN; MEMBRANE DEPOLARIZATION; MOTOR NERVE; NERVE POTENTIAL; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NEUROTRANSMITTER RELEASE; STRUCTURE ACTIVITY RELATION;

EID: 84871531217     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12001     Document Type: Article

References (61)

1. Lambert, E.H., L.M. Eaton & E.D. Rooke. 1956. Defect of neuromuscular conduction associated with malignant neoplasm. Am. J. Physiol. 187: 612-613.
2. Titulaer, M.J., B. Lang & J.J. Verschuuren. 2011. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 10: 1098-1107.
3. Payne, M., P. Bradbury, B. Lang, et al. 2011. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J. Thorac. Oncol. 5: 34-8.
4. Gilhus, N.E. 2012. Myasthenia and the neuromuscular junction. Curr. Opin. Neurol. 25: 523-529.
5. Vincent, A., B. Lang & J. Newsom-Davis. 1989. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 12: 496-502.
6. Nagel, A., A.G. Engel, B. Lang, et al. 1988. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann. Neurol. 24: 552-558.
7. Meriney, S.D., S.C. Hulsizer, V.A. Lennon & A.D. Grinnell. 1996. Lambert-Eaton myasthenic syndrome IgG removes multiple types of calcium channels from a human small cell lung cancer cell line. Ann. Neurol. 40: 739-749.
8. Abicht, A. & H. Lochmuller. 2002. What's in the serum of seronegative MG and LEMS Neurology 59: 1672-1673.
9. Raymond, C., D. Walker, D. Bichet, et al. 1999. Antibodies against the beta subunit of voltage-dependent calcium channels in Lambert-Eaton myasthenic syndrome. Neuroscience 90: 269-277.
10. Takamori, M., K. Komai & K. Iwasa. 2000. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am. J. Med. Sci. 319: 204-208.
11. Flink, M.T. & W.D. Atchison. 2002. Passive transfer of Lambert-Eaton syndrome to mice induced dihydropyridine sensitivity of neuromuscular transmission. J. Physiol. 543: 567-576.
12. Smith, D.O., M.W. Conklin, P.J. Jensen & W.D. Atchison. 1995. Decreased calcium currents in motor nerve terminals of mice with Lambert-Eaton myasthenic syndrome. J. Physiol. 487: 115-123.
13. Skeie, G.O., S. Apostolski, A. Evoli, et al., European Federation of Neurological Societies. 2010. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 17: 893-902.
14. Verschuuren, J.J., P.W. Wirtz, M.J. Titulaer, et al. 2006. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin. Pharmacother. 7: 1323-1336.
15. Wirtz, P.W., J.J. Verschuuren, J.G. van Dijk, et al. 2009. Efficacy of 3, 4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin. Pharmacol. Ther. 86: 44-48.
16. Oh, S.J., G.G. Claussen, Y. Hatanaka & M.B. Morgan. 2009. 3, 4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 40: 795-800.
17. Sanders, D.B., J.M. Massey, L.L. Sanders & L.J. Edwards. 2000. A randomized trial of 3, 4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54: 603-607.
18. Miralles, F. & C. Solsona. 1998. 3, 4diaminopyridine-induced impairment in frog motor nerve terminal response to high frequency stimulation. Brain Res. 789: 239-244.
19. Thomsen, R.H. & D.F. Wilson. 1983. Effects of 4-aminopyridine and 3, 4diaminopyridine on transmitter release at the neuromuscular junction. J. Pharmacol. Exp. Ther. 227: 260-265.
20. Tarr, T.B., W. Malick, M. Liang, et al. 2012. Evaluation of a Novel Calcium Channel Agonist for Potential Therapeutic Activity in LEMS and other Neuromuscular Diseases. Program No. 653.31. 2012 Neuroscience Meeting Planner. Society for Neuroscience. New Orleans, LA, 2012. Online.
21. Liang, M., T.B. Tarr, K. Bravo-Altamirano, et al. 2012. Synthesis and biological evaluation of a new calcium channel agonist. ACS Med. Chem. Lett. 3: 985-990.
22. Paglini, G. & A. Caceres. 2001. The role of the Cdk5-p35 kinase in neuronal development. Eur. J. Biochem. 268: 1528-1533.
23. Cheng, K. & N.Y. Ip. 2003. Cdk5: a new player at synapses. NeuroSignals 12: 180-190.
24. Kesavapany, S., B.S. Li & H.C. Pant. 2003. Cyclin-dependent kinase 5 in neurofilament function and regulation. NeuroSignals 12: 252-264.
25. Smith, D. 2003. Cdk5 in neuroskeletal dynamics. NeuroSignals 12: 239-251.
26. Shelton, S.B. & G.V. Johnson. 2004. Cyclin-dependent kinase-5 in neurodegeneration. J. Neurochem. 88: 1313-1326.
27. Murray, A.W. 2004. Recycling the cell cycle: cyclins revisited. Cell 116: 221-234.
28. Monaco, E.A. & M.L. Vallano. 2003. Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians. Curr. Med. Chem. 10: 367-379.
29. Yan, Z., P. Chi, J.A. Bibb, et al. 2002. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J. Physiol. 540: 761-770.
30. Buraei, Z., M. Anghelescu & K.S. Elmslie. 2005. Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine. Biophys J. 89: 1681-1691.
31. Cho, S. & S.D. Meriney. 2006. The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur. J. Neurosci. 23: 3200-3208.
32. Tomizawa, K., J. Ohta, M. Matsushita, et al. 2002. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J. Neurosci. 22: 2590-2597.
33. Buraei, Z., G. Schofield & K.S. Elmslie. 2007. Roscovitine differentially affects CaV2 and Kv channels by binding to the open state. Neuropharmacology 52: 883-894.
34. DeStefino, N.R., A.A. Pilato, M. Dittrich, et al. 2010. (R)-Roscovitine prolongs the mean open time of unitary N-type calcium channel currents. Neuroscience 167: 838-849.
35. Protti, D.A., R. Reisin, T.A. Mackinley & O.D. Uchitel. 1996. Calcium channel blockers and transmitter release at the normal human neuromuscular junction. Neurology 46: 1391-1396.
36. Urbano, F.J., M.R. Pagani & O.D. Uchitel. 2008. Calcium channels, neuromuscular synaptic transmission and neurological diseases. J. Neuroimmunol. 201-202: 136-144.
37. Sheng, Z.H., R.E. Westenbroek & W.A. Catterall. 1998. Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking/fusion machinery. J. Bioenerg. Biomembr. 30: 335-345.
38. Palace, J., C.M. Wiles & J. Newsom-Davis. 1991. 3, 4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J. Neurol. Neurosurg. Psychiatr. 54: 1069-1072.
39. Harper, C.M. 2004. Congenital myasthenic syndromes. Semin. Neurol. 24: 111-123.
40. Pelufo-Pellicer, A., E. Monte-Boquet, E. Romá-Sánchez, et al. 2006. Fetal exposure to 3, 4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome. Ann. Pharmacother. 40: 762-766.
41. Engel, A.G., X.M. Shen, D. Selcen & S.M. Sine. 2009. What have we learned from the congenital myasthenic syndromes. J. Mol. Neurosci. 40: 143-153.
42. Patrick, J. & J. Lindstrom. 1973. Autoimmune response to acetylcholine receptors. Science 180: 871-872.
43. Meriggioli, M.N. & D.B. Sanders. 2009. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 8: 475-490.
44. Gilhus, N.E., J.F. Owe, J.M. Hoff, et al. 2011. Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis. 2011: 1-6.
45. Sathasivam, S. 2011. Current and emerging treatments for the management of myasthenia gravis. Ther. Clin. Risk Manag. 7: 313-23.
46. Mann, J.M., S. Martin, R. Hoffman & S. Marrazzo. 1981. Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am. J. Public Health 1: 266-269.
47. Wilcox, P., G. Andolfatto, M.S. Fairbarn & R.L Pardy. 1989. Long-term follow-up of symptoms, pulmonary function, respiratory muscle strength, and exercise performance after botulism. Am. Rev. Respir. Dis. 139: 157-163.
48. Crowner, B.E., D. Torres-Russotto, A.R, Carter & B.A. Racette. 2010. Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin. Neuropharmacol. 33: 243-247.
49. Dressler, D. 2010. Subclinical myasthenia gravis causing increased sensitivity to botulinum toxin therapy. J. Neural. Transm. 117: 1293-1294.
50. 2+ channel activator, in cardiac and vascular preparations. Mol. Pharmacol. 40: 734-741.
51. Hess, P., J.B. Lansman & R.W. Tsien. 1984. Different modes of Ca channel gating behavior favoured by dihydropyridine Ca agonists and antagonists. Nature 311: 538-544.
52. Church, P.J. & E.F. Stanley. 1996. Single L-type calcium channel conductance with physiological levels of calcium in chick ciliary ganglion neurons. J. Physiol. 496: 59-68.
53. Yu, C., M. Jia, M. Litzinger & P.G. Nelson. 1988. Calcium agonist (BayK 8644) augments voltage-sensitive calcium currents but not synaptic transmission in cultured mouse spinal cord neurons. Exp. Brain Res. 71: 467-474.
54. 2+ channels in GABAergic synaptic transmission in cultured hippocampal neurons. J. Neurophysiol. 81: 1225-1230.
55. 2+ responses mediated by presynaptic L-type channels on GABAergic boutons of cultured hippocampal neurons. Brain Res. 1249: 79-90.
56. Mitterdorfer, J., Z. Wang, M.J. Sinnegger, et al. 1996. Two amino acid residues in the IIIS5 segment of L-type calcium channels differentially contribute to 1, 4-dihydropyridine sensitivity. J. Biol. Chem. 271: 30330-30335.
57. Grabner, M., Z. Wang, S. Hering, et al. 1996. Transfer of 1, 4-dihydropyridine sensitivity from L-type to class A (BI) calcium channels. Neuron 16: 207-218.
58. Erxleben, C., C. Gomez-Alegria, T. Darden, et al. 2003. Modulation of cardiac Ca(V)1.2 channels by dihydropyridine and phosphatase inhibitor requires Ser-1142 in the domain III pore loop. Proc. Natl. Acad. Sci. USA 100: 2929-2934.
59. Hui, K., P. Gardzinski, H.S. Sun, et al. 2005. Permeable ions differentially affect gating kinetics and unitary conductance of L-type calcium channels. Biochem Biophys. Res. Commun. 338: 783-792.
60. Katoh, H., K. Schlotthauer & D.M. Bers. 2000. Transmission of information from cardiac dihydropyridine receptor to ryanodine receptor: evidence from BayK 8644 effects on resting Ca(2+) sparks. Circ. Res. 87: 106-111.
61. 2+ channels-integration centers for neuronal signaling pathways. Trends Neurosci. 29: 617-624.